(IBB) Biotechnology - Overview
ETF Category: Health | Exchange: NASDAQ (USA) | Market Cap: 7.944m USD | Total Return: 32.3% in 12m
Avg Turnover: 248M
Warnings
No concerns identified
Tailwinds
No distinct edge detected
The iShares Biotechnology ETF (IBB) tracks the investment results of an index composed of U.S.-listed equities in the biotechnology sector. The fund maintains a mandate to invest at least 80% of its assets in the component securities of its underlying index, with the remaining 20% available for derivatives, cash equivalents, and other financial instruments to manage liquidity or track performance.
Biotechnology companies focus on the research, development, and commercialization of new drug therapies and diagnostic tools, often characterized by high research and development (R&D) expenses and long regulatory approval cycles. Unlike traditional pharmaceutical firms, biotech business models frequently rely on intellectual property and patent protection for biological products derived from living organisms.
As a non-diversified fund, IBB may hold larger positions in a smaller number of issuers, which can increase volatility relative to the broader market. You might find ValueRay useful for evaluating how these individual holdings align with your specific risk tolerance.
- FDA drug approval decisions impact valuation of top-weighted portfolio holdings
- Medicare price negotiation rules pressure long-term revenue growth for member firms
- M&A activity levels among large-cap biopharma drive sector-wide premium valuations
- Interest rate fluctuations dictate capital availability for research and development spending
- Clinical trial success rates for late-stage therapies determine fund performance volatility
As of June 08, 2026, the stock is trading at USD 168.44 with a total of 1,476,909 shares traded.
Over the past week, the price has changed by -2.17%,
over one month by -0.98%,
over three months by -1.59% and
over the past year by +32.33%.
Biotechnology has no consensus analysts rating.